Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market is expected to reach US$ 1,901.4 million by 2030

Consumables Segment, by Product, to Dominate Fluorescence In-Situ Hybridization (FISH) Imaging Systems During 2022–2030

According to our new research study on "Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market Size and Forecast (2020–2030), Global and Regional Share, Trends, and Growth Opportunity Analysis," the market is expected to grow from US$ 1,084.0 million in 2022 and is expected to reach a value of US$ 1,901.4 million by 2030; it is anticipated to record a CAGR of 7.3% from 2022 to 2030. Key factors driving the fluorescence in-situ hybridization (FISH) imaging systems market growth are rising prevalence of target disorders and increasing R&D investments in in-vitro diagnostics. However, the high cost of FISH imaging systems and procedures hinders the market growth.

FISH imaging systems are witnessing a remarkable evolution due to the surge in technological advancements, which result in cutting-edge innovations transforming the landscape of genetic research and diagnostics. These advancements include enhanced optics, more sensitive and versatile fluorophores, and sophisticated automation features. Modern FISH imaging systems, integrated with these upgraded features, offer greater sensitivity, improved image resolution, and faster processing times. Moreover, these technological advancements have extended the application scope of FISH imaging from cancer diagnosis to genetic predisposition testing. In July 2021, BioView and Capio Biosciences collaborated to create a platform for collecting circulating tumor cells (CTCs) from whole blood. These companies further improved the CTC liquid biopsy downstream analysis by integrating their technologies. Similarly, in collaboration, BioView and Capio Biosciences partnered with RUBYnanomed in December 2020 to create a unique imaging solution to accelerate the acceptance and adoption of CTC technology in clinics to enhance cancer detection. Thus, technological advancements in FISH imaging systems create significant opportunities for companies in the fluorescence in-situ hybridization (FISH) imaging systems market.

Fluorescence In-Situ Hybridization (FISH) Imaging Systems Market, by Geography, 2022 (%)

Source: The Insight Partners Analysis

Euroclone SpA, TissueGnostics GmbH, Agilent Technologies Inc, Abnova Taiwan Corp, BioGenex Laboratories Inc, Leica Biosystems Nussloch GmbH, MetaSystems Probes GmbH, Bio-View Ltd, Thermo Fisher Scientific Inc, Applied Spectral Imaging, and PerkinElmer Inc are among the key companies operating in the fluorescence in-situ hybridization (FISH) imaging systems market. The companies have been implementing various strategies that contributed to their growth and led to various changes in the market. The companies have utilized both organic strategies (such as launches, expansion, and product approvals) and inorganic strategies (such as product launches, partnerships, and collaborations).

For instance, in May 2022, MetaSystems Probes GmbH launched three new XCyting locus-specific break-apart probes—XL TCL1 BA, XL SPI1 BA, and XL CSF1R BA—to its hematology and oncology portfolio. The XL TCL1 BA is designed to detect TCL1 gene cluster locus involving rearrangements described in several T-cell prolymphocytic leukemia (T-PLL) cases. The XL SPI1 BA is suitable for detecting the SPI1 gene locus involving rearrangements in pediatric T-cell acute lymphocytic leukemia (T-ALL) cases. The XL CSF1R BA is one of the prominent genes involved in multiple rearrangements described in a high-risk subset of ALL disorders, which account for B-cell precursor ALLs.

The report segments the fluorescence in-situ hybridization (FISH) imaging systems market as follows:

The fluorescence in-situ hybridization (FISH) imaging systems market, by product, is segmented into instruments, consumables, accessories, and software. The consumables segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022–2030. Consumables are the most promising segment of the fluorescence in-situ hybridization (FISH) imaging system market that will contribute to tremendous growth in the coming years. FISH consumables include hybridization buffers, probes, tag detection kits, signal amplification detection kits, and others. The presence of manufacturers such as Abbott, F. Abnova, and Thermo Fisher Scientific bolsters the market for the consumables segment. These products are frequently used in various research diagnosis processes, which is expected to propel consumption. Thus, the presence of various market players offering probes & kits and technological advancements by market players are likely to propel the market for the segment in the coming years. Based on application, the fluorescence in-situ hybridization (FISH) imaging systems market is segmented into cancer diagnosis, genetic disease diagnosis, infectious disease diagnosis, and others. The cancer diagnosis segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022–2030. Based on end user, the fluorescence in-situ hybridization (FISH) imaging systems market is segmented into diagnostic laboratories, contract research organization, pharmaceutical and biotechnological companies, and others. The diagnostic laboratories segment held the largest market share in 2022 and is anticipated to register the highest CAGR during 2022–2030.

Based on geography, the fluorescence in-situ hybridization (FISH) imaging systems market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com